Edesa Biotech, Inc.
Edesa Biotech, Inc. (EDSA): 4 pipeline candidates · ~15 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
15.1 months
0% dilution
Lead: Phase 3
4 candidates
N/A
9 buys · 0 sells (180d)
A transparent, data-derived signal for Edesa Biotech, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$56.2M
Cash
$10.0M
Quarterly Burn
$2.0M
Runway
15.1 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (4 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
25
Total value held
$9.0M
| Holder | Shares | Value |
|---|---|---|
| perceptive advisors llc | 1,126,478 | $5.9M |
| vanguard capital management llc | 171,932 | $899K |
| jane street group, llc | 115,721 | $605K |
| geode capital management, llc | 77,054 | $403K |
| vanguard fiduciary trust co | 38,446 | $201K |
| state street corp | 37,979 | $199K |
| commonwealth equity services, llc | 35,003 | $183K |
| stonepine capital management, llc | 30,000 | $157K |
| blackrock, inc. | 27,709 | $145K |
| schonfeld strategic advisors llc | 19,650 | $103K |
Showing top 10 of 25 institutional holders of Edesa Biotech, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Edesa Biotech, Inc.'s pipeline?
Edesa Biotech, Inc. (EDSA) has 4 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Edesa Biotech, Inc.'s lead drug candidate?
Edesa Biotech, Inc.'s most advanced tracked candidate is eb01 (Phase 2) for Allergic Contact Dermatitis (ACD).
What is Edesa Biotech, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Edesa Biotech, Inc. has approximately 15.1 months of cash runway.
What is Edesa Biotech, Inc.'s market capitalization?
Edesa Biotech, Inc.'s market capitalization is approximately $56.2M.
Who is the CEO of Edesa Biotech, Inc.?
Dr. Pardeep Nijhawan FRCPC, M.D. is the chief executive officer of Edesa Biotech, Inc. (EDSA).
Get the full picture on Edesa Biotech, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.